Digoxin Discontinuation and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction.
Aged
Cardiotonic Agents
/ administration & dosage
Cause of Death
Digoxin
/ administration & dosage
Female
Heart Failure
/ drug therapy
Humans
Male
Outpatients
Patient Readmission
/ trends
Propensity Score
Registries
Retrospective Studies
Risk Factors
Stroke Volume
/ physiology
Survival Rate
/ trends
Treatment Outcome
United States
/ epidemiology
Withholding Treatment
digoxin discontinuation
heart failure
mortality
readmission
reduced ejection fraction
Journal
Journal of the American College of Cardiology
ISSN: 1558-3597
Titre abrégé: J Am Coll Cardiol
Pays: United States
ID NLM: 8301365
Informations de publication
Date de publication:
06 08 2019
06 08 2019
Historique:
received:
07
04
2019
revised:
23
05
2019
accepted:
28
05
2019
entrez:
3
8
2019
pubmed:
3
8
2019
medline:
19
5
2020
Statut:
ppublish
Résumé
The deleterious effects of discontinuation of digoxin on outcomes in ambulatory patients with chronic heart failure (HF) with reduced ejection fraction (HFrEF) receiving angiotensin-converting enzyme inhibitors are well-documented. The authors sought to determine the relationship between digoxin discontinuation and outcomes in hospitalized patients with HFrEF receiving more contemporary guideline-directed medical therapies including beta-blockers and mineralocorticoid receptor antagonists. Of the 11,900 hospitalized patients with HFrEF (EF ≤45%) in the Medicare-linked OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) registry, 3,499 received pre-admission digoxin, which was discontinued in 721 patients. Using propensity scores for digoxin discontinuation, estimated for each of the 3,499 patients, a matched cohort of 698 pairs of patients, balanced on 50 baseline characteristics (mean age 76 years; mean EF 28%; 41% women; 13% African American; 65% on beta-blockers) was assembled. Four-year post-discharge, digoxin discontinuation was associated with significantly higher risks of HF readmission (hazard ratio [HR]: 1.21; 95% confidence interval [CI]: 1.05 to 1.39; p = 0.007), all-cause readmission (HR: 1.16; 95% CI: 1.04 to 1.31; p = 0.010), and the combined endpoint of HF readmission or all-cause mortality (HR: 1.20; 95% CI: 1.07 to 1.34; p = 0.002), but not all-cause mortality (HR: 1.09; 95% CI: 0.97 to 1.24; p = 0.163). Discontinuation of digoxin was associated with a significantly higher risk of all 4 outcomes at 6 months and 1 year post-discharge. At 30 days, digoxin discontinuation was associated with higher risks of all-cause mortality (HR: 1.80; 95% CI: 1.26 to 2.57; p = 0.001) and the combined endpoint (HR: 1.36; 95% CI: 1.09 to 1.71; p = 0.007), but not of HF readmission (HR: 1.19; 95% CI: 0.90 to 1.59; p = 0.226) or all-cause readmission (HR: 1.03; 95% CI: 0.84 to 1.26; p = 0.778). Among hospitalized older patients with HFrEF on more contemporary guideline-directed medical therapies, discontinuation of pre-admission digoxin therapy was associated with poor outcomes.
Sections du résumé
BACKGROUND
The deleterious effects of discontinuation of digoxin on outcomes in ambulatory patients with chronic heart failure (HF) with reduced ejection fraction (HFrEF) receiving angiotensin-converting enzyme inhibitors are well-documented.
OBJECTIVES
The authors sought to determine the relationship between digoxin discontinuation and outcomes in hospitalized patients with HFrEF receiving more contemporary guideline-directed medical therapies including beta-blockers and mineralocorticoid receptor antagonists.
METHODS
Of the 11,900 hospitalized patients with HFrEF (EF ≤45%) in the Medicare-linked OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) registry, 3,499 received pre-admission digoxin, which was discontinued in 721 patients. Using propensity scores for digoxin discontinuation, estimated for each of the 3,499 patients, a matched cohort of 698 pairs of patients, balanced on 50 baseline characteristics (mean age 76 years; mean EF 28%; 41% women; 13% African American; 65% on beta-blockers) was assembled.
RESULTS
Four-year post-discharge, digoxin discontinuation was associated with significantly higher risks of HF readmission (hazard ratio [HR]: 1.21; 95% confidence interval [CI]: 1.05 to 1.39; p = 0.007), all-cause readmission (HR: 1.16; 95% CI: 1.04 to 1.31; p = 0.010), and the combined endpoint of HF readmission or all-cause mortality (HR: 1.20; 95% CI: 1.07 to 1.34; p = 0.002), but not all-cause mortality (HR: 1.09; 95% CI: 0.97 to 1.24; p = 0.163). Discontinuation of digoxin was associated with a significantly higher risk of all 4 outcomes at 6 months and 1 year post-discharge. At 30 days, digoxin discontinuation was associated with higher risks of all-cause mortality (HR: 1.80; 95% CI: 1.26 to 2.57; p = 0.001) and the combined endpoint (HR: 1.36; 95% CI: 1.09 to 1.71; p = 0.007), but not of HF readmission (HR: 1.19; 95% CI: 0.90 to 1.59; p = 0.226) or all-cause readmission (HR: 1.03; 95% CI: 0.84 to 1.26; p = 0.778).
CONCLUSIONS
Among hospitalized older patients with HFrEF on more contemporary guideline-directed medical therapies, discontinuation of pre-admission digoxin therapy was associated with poor outcomes.
Identifiants
pubmed: 31370952
pii: S0735-1097(19)35613-X
doi: 10.1016/j.jacc.2019.05.064
pmc: PMC10465068
mid: NIHMS1532196
pii:
doi:
Substances chimiques
Cardiotonic Agents
0
Digoxin
73K4184T59
Types de publication
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
617-627Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL085561
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL097047
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
Published by Elsevier Inc.
Références
J Am Coll Cardiol. 1995 Feb;25(2):289-94
pubmed: 7829779
N Engl J Med. 1993 Jul 1;329(1):1-7
pubmed: 8505940
Eur Heart J. 2006 Jan;27(2):178-86
pubmed: 16339157
Circulation. 1989 Jul;80(1):65-77
pubmed: 2736756
J Am Coll Cardiol. 1989 Jan;13(1):134-42
pubmed: 2562844
Int J Cardiol. 2013 Jun 5;166(1):230-5
pubmed: 22119116
Cardiovasc Res. 1991 Aug;25(8):684-91
pubmed: 1655269
J Am Coll Cardiol. 2007 Aug 21;50(8):768-77
pubmed: 17707182
Clin Cardiol. 2018 Mar;41(3):406-412
pubmed: 29569405
J Am Coll Cardiol. 2013 Oct 15;62(16):e147-239
pubmed: 23747642
Am J Cardiol. 2007 Jul 15;100(2):280-4
pubmed: 17631083
Am J Med. 2019 Jan;132(1):71-80.e1
pubmed: 30240686
Circulation. 1991 Nov;84(5):2181-6
pubmed: 1834367
J Am Coll Cardiol. 1997 May;29(6):1206-13
pubmed: 9137214
J Am Coll Cardiol. 1993 Oct;22(4):955-62
pubmed: 8409069
Am J Med. 2013 Feb;126(2):150-61
pubmed: 23331442
Lancet. 2005 Jan 8-14;365(9454):176-86
pubmed: 15639301
Am J Med. 1982 Aug;73(2):244-50
pubmed: 7051826
Eur Heart J. 2009 Aug;30(16):2029-37
pubmed: 19531579
Am Heart J. 2004 Jul;148(1):43-51
pubmed: 15215791
Eur Heart J. 2006 Jun;27(12):1431-9
pubmed: 16709595
Am J Physiol. 1972 Jun;222(6):1398-405
pubmed: 4260538
J Cardiovasc Pharmacol. 1983 Mar-Apr;5(2):229-34
pubmed: 6188895
Am J Med. 1983 Sep;75(3):445-7
pubmed: 6351608
Am J Med. 2018 Dec;131(12):1473-1481
pubmed: 30076815
Am J Med. 2013 May;126(5):401-10
pubmed: 23510948
Multivariate Behav Res. 2011 May;46(3):399-424
pubmed: 21818162
Am J Med. 2013 Aug;126(8):701-8
pubmed: 23490060
N Engl J Med. 1997 Feb 20;336(8):525-33
pubmed: 9036306
Am J Med. 2014 Jan;127(1):61-70
pubmed: 24257326
Circulation. 1979 Jun;59(6):1158-64
pubmed: 436208
Am J Med. 2012 Apr;125(4):399-410
pubmed: 22321760
N Engl J Med. 2009 Apr 2;360(14):1418-28
pubmed: 19339721
Am J Med. 2019 Nov;132(11):1311-1319
pubmed: 31150644
JACC Heart Fail. 2016 May;4(5):348-56
pubmed: 26874392
Br Heart J. 1994 Nov;72(5):422-7
pubmed: 7818958
Eur J Heart Fail. 2013 May;15(5):551-9
pubmed: 23355060